Global Community

Below is a sell-side / investment banking style investment memo on Village Farms International (NASDAQ: VFF), fully based on the Q1 2026 results and FY2025 10-K annual report you provided, with verified data points and citations. Village Farms International (VFF) – Investment Memo Date: May 2026 Executive Summary Village Farms International (“Village Farms” or the “Company”) is a vertically integrated, low-cost cannabis producer with a differentiated heritage in Controlled Environment Agriculture (CEA).Read more

Jarir Marketing continues to show a stable financial profile, supported by strong brand positioning, steady profitability, and a high dividend payout policy. The company reported revenue of SAR 11.45bn in 2025, compared with SAR 10.91bn in 2024, while net profit reached SAR 1.05bn.Read more

🪙 Blackrock Silver Corp. (TSXV: BRC) Blackrock Silver is a high-grade silver–gold developer/explorer advancing Tonopah West in Nevada.Read more

Archer Aviation is positioned to be the first to scale in the trillion-dollar Urban Air Mobility (UAM) market. Unlike competitors struggling with "production hell," Archer has solved the manufacturing equation through its strategic partnership with Stellantis , which is funding and building Archer's high-volume factory in Georgia.Read more

The Valuation Model: The Math Behind the $6.65 Target Our valuation is built on a theoretical 2031 "Bull Case" scenario, assuming the successful execution of Commercial Phase 1 and the initiation of Phase 2 at the Fort Cady facility. 2031 Projected Revenue: $550,000,000 USD (Driven by core boric acid production and a ~20% shift into high-margin advanced derivatives like Meta Boric Acid and Ferroboron).Read more

Take-Two Interactive Software Inc. is a company which develops and makes action games, particularly mobile, console, computer and on-line games.Read more

Wasco Greenergy Berhad remains optimistic on its growth trajectory despite a softer first quarter FY2026, with management highlighting that its expanding renewable energy pipeline , resilient order book and regional growth initiatives continue to position the group well for stronger recovery ahead. The group recorded revenue of RM54.4 million for the first quarter ended 31 March 2026 compared with RM61.4 million in the corresponding quarter last year, while profit before tax stood at RM4.9 million versus RM6.3 million previously.Read more

Below is a fact-checked, integrated investment memo on Paradigm Biopharmaceuticals (ASX: PAR), made with copilot help, (if you find any errors, please let me know); combining validation of AmirV claims with external sources and a professional investment framework. Investment Memo: Paradigm Biopharmaceuticals (ASX: PAR) Ticker: PAR (ASX) Sector: Biotechnology (Late-stage clinical) Core Asset: Zilosul® (injectable pentosan polysulfate sodium, PPS) Date: May 2026 1.Read more

Q4 FY12/25 results update Strong trajectory is projected to sustain into FY12/26 – FY12/25 ended strongly, where OP surged by 35.8%, driven by favorable industry tailwinds and substantial margin expansion across both the Workplace and Equipment segments. We expect this upward trajectory to persist through FY12/26, underpinned by the company's comprehensive efforts to strengthen corporate governance, realize group-wide synergies, and accelerate its AI-driven technological transformation, particularly in "Office 3.0" consulting and data-driven services.Read more